English
Regional settings| Spread | 0.05 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 6.13 |
| Open | 6.13 |
| 1-Year Change | -64.71% |
| Day's Range | 6.13 - 6.55 |
Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP1 (vusolimogene oderparepvec), RP2, and RP3. The Company is focused on Phase 2 clinical trials with its lead product candidate, RP1, in approximately 240 patients with a range of solid tumors.
BRIEF: For the nine months ended 31 December 2021, Replimune Group Inc revenues was not reported. Net loss increased 45% to $86.3M. Higher net loss reflects Research and development increase of 41% to $49.7M (expense), Stock-based Compensation in SGA increase from $4.6M to $12M (expense), General and administrative increase of 38% to $16.1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.34 to -$1.66.
